Patents by Inventor David D. Eveleth

David D. Eveleth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of metabotropic receptor agonists in progressive neurodegenerative diseases
    Patent number: 5622981
    Abstract: A method of treating a mammal with a neurodegenerative disease which is caused at least in part by the neurotoxic effects of the .beta.-amyloid protein. This method constitutes administering a metabotropic receptor agonist to such a mammal. In particular, the agonist trans-ACPD or 1S,3R-ACPD can be administered intravenously to treat a mammal with Alzheimer's disease.
    Type: Grant
    Filed: April 7, 1995
    Date of Patent: April 22, 1997
    Assignee: Cortex Pharmaceuticals, Inc.
    Inventors: David D. Eveleth, Judith A. Kelleher, Carl W. Cotman
  • Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
    Patent number: 5567724
    Abstract: The present invention provides a method of inhibiting .beta.-amyloid toxicity in brain cells. The method includes administering to the cells an amount of an alkaline phosphatase inhibitor which is pharmacologically effective to reduce degeneration in the cells. Methods of treatment of peripheral neuropathy are also provided using acid or alkaline phosphatase inhibitors.
    Type: Grant
    Filed: June 1, 1994
    Date of Patent: October 22, 1996
    Assignee: Cortex Pharmaceuticals, Inc.
    Inventors: Judith A. Kelleher, David D. Eveleth
  • Method of treatment of neurodegeneration with calpain inhibitors
    Patent number: 5444042
    Abstract: The present invention provides a method of treating a neurodegenerative pathology in a human patient. This method includes selecting a patient for monitoring for the presence of a neurodegenerative pathology associated with enhanced Calpain activity and monitoring the patient for indicia of the onset or existence of such a pathology. In response to the detection of any such indicium of the presence or onset of the pathology, a therapeutically efficacious amount of a Peptide Ketoamide compound, or a pharmaceutically acceptable salt or derivative thereof, together with a pharmaceutically acceptable carrier is administered. The invention also provides additional methods of treatment and pharmaceutical compositions using Peptide Ketoamides, Peptide Ketoacids and Peptide Ketoesters.
    Type: Grant
    Filed: March 7, 1994
    Date of Patent: August 22, 1995
    Assignees: Cortex Pharmaceuticals, Georgia Tech Research Corporation (GTRC)
    Inventors: Raymond T. Bartus, David D. Eveleth, James C. Power
  • Methods for detecting cellular pathology by assaying spectrin and spectrin breakdown products
    Patent number: 5118606
    Abstract: The invention provides a method for the detection of cellular pathology by means of an immunoassay to determine the presence of stable breakdown products, termed BDP's or BDP1 and BDP2, of the cytoskeleton component spectrin. In one aspect of the invention, the components from a sample of spectrin-containing cells are physically separated, as by exposure to an electric field, in such a way that BDP and spectrin are separated. Antibodies reactive with BDP are then contacted with the separated sample, and their binding to that portion of the sample containing any BDP determined. In another aspect of the invention, an assay, such as an ELISA assay, is performed to detect total spectrin immunoreactivity as an indication of cellular death or degradation.
    Type: Grant
    Filed: July 26, 1990
    Date of Patent: June 2, 1992
    Assignee: The Regents of the University of California
    Inventors: Gary S. Lynch, Peter A. Seubert, David D. Eveleth, Jr.